Medigen Biotechnology Corp.


President: Dr. Stanley Chang
Funded Date: 1999/12/31 
Tel: 886-2-2653-5200 
Fax: 886-2-2785-6120 
Address: 14F, No. 3, Park St., Nangang District, Taipei City, Taiwan  
Website: http://www.medigen.com.tw/


 

Company Profile:

Medigen Biotechnology Corporation upholds the vision of “Innovations for a Better Life” focusing on the development of new therapies for liver diseases and cancers. Medigen has devoted our focus on bringing innovative solutions in the fields of new drug development, molecular diagnostics and cell-based vaccine technology. With more than 15 years of experience, Medigen has gradually developed into a comprehensive biopharmaceutical corporation with business fields covering new drug development, innovative drug discovery, molecular diagnostics, vaccine, and generic drug manufacturing and marketing. We believes that, through our core value of “Compassion” ”Integrity” “Innovation” and “Professionalism “, Medigen will become Asia leading Biotechnology Company in the future.

New Drug in Development:

Products

Indication

Mechanism

Development Stage

PI-88
(Muparfostat)

Adjuvant therapy for HCC after curative surgery

Anti-metastasis and anti-angiogenesis

CFDA, TFDA, HKDOH and MFDS approved global phase III trial, recruitment completed

OBP-301

Unresectable HCC

Oncolytic virotherapy

TFDA and MFDS approved phase I/ II trial, recruiting

EV71vac

Prophylactic vaccine for Enterovirus 71

Immune response induced by EV71 vaccine

Phase II trial, recruiting

AT-301

Prophylactic vaccine for H5N1 Avian Flu

Immune response induced by H5N1 vaccine

Phase I trial, completed